Vinay Raja, MD
Hematology & Oncology · North Kansas City, MONPI 1386677938
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,446 of the $30,120 with a category attached, or 71.2%. 18 manufacturers reported payments, led by Incyte Corporation at 40.0% of the total. Reporting peaked in 2023 at $7,656 and has fallen 63.8% since, to $2,775 in 2025. Among hematology & oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $449.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$12K
- AstraZeneca$9K
- Athenex Pharmaceutical Division, LLC$4K
- Daiichi Sankyo Inc.$1K
- Lilly USA, LLC$1K
- Beigene USA, Inc.$675
- plus $2K from 12 others
Across 10 payments — averaging $6378.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$63K
- Merck$842
What the payments were for
- Consulting fees$21,44671%
- Speaking & faculty fees$4,97517%
- Travel & lodging$1,9867%
- Food & beverage$6152%
- Education$1,0984%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 17 | $12,057 |
| AstraZeneca | 13 | $9,292 |
| Athenex Pharmaceutical Division, LLC | 4 | $4,025 |
| Daiichi Sankyo Inc. | 3 | $1,400 |
| Lilly USA, LLC | 10 | $1,074 |
| Beigene USA, Inc. | 1 | $675 |
| EMD Serono, Inc. | 1 | $500 |
| Cardinal Health 110 LLC | 2 | $375 |
| Novocure GmbH | 1 | $200 |
| Covis Pharma GmbH | 1 | $200 |
| AbbVie | 6 | $190 |
| Merck | 2 | $30 |
| GSK | 1 | $24 |
| Sobi, Inc | 1 | $24 |
| Pfizer | 1 | $17 |
| Novartis | 1 | $13 |
| Gilead | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$5,828
- Oral Paclitaxel$3,850
- Encequidar$3,850
- TAGRISSO$2,800
- BRUKINSA$675
- VANFLYTa$650
- CALQUENCE$525
- Tepmetko$500
- RETEVMO$456
How this compares
$30,120 in reported general payments places this provider in the 90th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 44 | $612,308 |
| JakafiRuxolitinib Phosphate | 30 | $473,574 |
| Lenalidomide | 28 | $359,762 |
| RevlimidLenalidomide | 17 | $320,562 |
| CalquenceAcalabrutinib Maleate | 21 | $303,366 |
| ImbruvicaIbrutinib | 27 | $209,904 |
| OrgovyxRelugolix | 12 | $30,252 |
| Abiraterone Acetate | 20 | $9,200 |
| EliquisApixaban | 14 | $8,103 |
| Morphine Sulfate ErMorphine Sulfate | 16 | $1,120 |
| Imatinib Mesylate | 14 | $1,021 |
| Exemestane | 12 | $985 |
| Oxycodone Hcl | 33 | $776 |
| Anastrozole | 42 | $665 |
| Acyclovir | 24 | $645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $675 | $612,30844 claims |
| Incyte CorporationJakafi | $12,057 | $473,57430 claims |
| AstraZenecaCalquence | $9,292 | $303,36621 claims |
| PfizerEliquis | $17 | $8,10314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in North Kansas City
- Benjamin FangmanNorth Kansas City$9K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.